Pacebo-controlled, double-blind, randomised phase II study with crossover-design investigating the modulatory effects of intranasal Oxytocin on social cognition in patients with Autism-Spectrum-Disorder - Social Cognition-Autism-Oxytocin
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs Oxytocin (Primary)
- Indications Asperger syndrome; Autistic disorder
- Focus Therapeutic Use
- 24 Apr 2017 Status changed from not yet recruiting to recruiting.
- 15 Sep 2016 New trial record
- 12 Sep 2016 Planned initiation date changed from 23 May 2016 to 30 Oct 2016.